<DOC>
	<DOCNO>NCT00103714</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability preliminary efficacy two dose level INS37217 ( denufosol tetrasodium ) Inhalation Solution patient cystic fibrosis ( CF ) lung disease .</brief_summary>
	<brief_title>Study Denufosol Tetrasodium Patients With Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>Have confirm diagnosis CF Have FEV1 great equal 60 % less equal 90 % predict normal Have oxygen saturation great equal 90 % room air Be clinically stable evidence acute upper low respiratory tract infection current pulmonary exacerbation Be able reproducibly perform spirometry maneuver Have change physiotherapy technique schedule within 7 day prior screen Have clinically significant comorbidities Using prior concurrent medication accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>lung disease</keyword>
</DOC>